Format

Send to

Choose Destination
J Nucl Med. 2014 Dec;55(12):1919-22. doi: 10.2967/jnumed.114.146019. Epub 2014 Nov 20.

Theranostic nanoparticles.

Author information

1
Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin fchen@uwhealth.org wcai@uwhealth.org.
2
Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin.
3
Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin Materials Science Program, University of Wisconsin-Madison, Madison, Wisconsin; and University of Wisconsin Carbone Cancer Center, Madison, Wisconsin fchen@uwhealth.org wcai@uwhealth.org.

Abstract

Theranostic nanoparticles hold the potential to revolutionize disease management. Over the last decade, there has been growing interest in the engineering of various kinds of theranostic nanoparticles for simultaneous cancer imaging and therapy in small animals. Efficient targeting of theranostic nanoparticles to the tumor site is critical for both diagnosis and therapy. However, difficulties still exist in the engineering of biocompatible theranostic nanoparticles with highly specific in vivo tumor-targeting capabilities. Here, we discuss the current and prospective status of theranostic nanoparticles that actively target tumors, as well as the challenges that still exist.

KEYWORDS:

active targeting; cancer; nanomedicine; theranostic nanoparticle; theranostics

PMID:
25413134
PMCID:
PMC4255955
DOI:
10.2967/jnumed.114.146019
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center